| Literature DB >> 26492824 |
Elena Aguilera1, Javier Varela1, Estefanía Birriel1, Elva Serna2, Susana Torres2, Gloria Yaluff2, Ninfa Vera de Bilbao2, Beatriz Aguirre-López3, Nallely Cabrera3, Selma Díaz Mazariegos3, Marieta Tuena de Gómez-Puyou3, Armando Gómez-Puyou3, Ruy Pérez-Montfort3, Lucia Minini4, Alicia Merlino4, Hugo Cerecetto1,5, Mercedes González1, Guzmán Alvarez6,7.
Abstract
Triosephosphate isomerase (TIM) is an essential Trypanosoma cruzi enzyme and one of the few validated drug targets for Chagas disease. The known inhibitors of this enzyme behave poorly or have low activity in the parasite. In this work, we used symmetrical diarylideneketones derived from structures with trypanosomicidal activity. We obtained an enzymatic inhibitor with an IC50 value of 86 nm without inhibition effects on the mammalian enzyme. These molecules also affected cruzipain, another essential proteolytic enzyme of the parasite. This dual activity is important to avoid resistance problems. The compounds were studied in vitro against the epimastigote form of the parasite, and nonspecific toxicity to mammalian cells was also evaluated. As a proof of concept, three of the best derivatives were also assayed in vivo. Some of these derivatives showed higher in vitro trypanosomicidal activity than the reference drugs and were effective in protecting infected mice. In addition, these molecules could be obtained by a simple and economic green synthetic route, which is an important feature in the research and development of future drugs for neglected diseases.Entities:
Keywords: Chagas disease; Trypanosoma cruzi; cruzipain; enzyme inhibitors; multitarget drugs; triosephosphate isomerase
Mesh:
Substances:
Year: 2015 PMID: 26492824 DOI: 10.1002/cmdc.201500385
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466